目的 探讨核糖核苷酸还原酶亚单位M2（RRM2）在肝细胞癌组织中的表达情况及其临床特征、预后相关性。方法 检索肿瘤基因组图谱（TCGA）数据库获取肝细胞癌转录组数据和临床相关资料数据，提取RRM2在肝细胞癌和癌旁组织中的表达数据，采用COX单因素、多因素分析RRM2与肝细胞癌患者临床和预后相关性。利用The Human Protein Atlas（HAP）数据库检索RRM2蛋白在肝细胞癌中的表达情况。结果 肝细胞癌组织中RRM2蛋白和mRNA表达均显著高于癌旁组织，且Ⅰ、Ⅱ期肝细胞癌组织中RRM2表达显著高于Ⅲ、Ⅳ期癌组织（P<0.01）。RRM2表达情况与肝细胞癌患者预后呈负相关（P<0.01）。COX单因素、多因素分析显示，肝细胞癌组织中RRM2表达水平、TNM分期是影响肝细胞癌预后的独立因素。结论 RRM2在肝细胞癌发生发展过程中可能发挥促进作用，是影响肝细胞癌患者预后的独立危险因素，其可能成为早期诊断肝细胞癌的分子标志物和判断预后的潜在指标，为RRM2抑制剂的研发提供理论基础。

Objective To investigate the expression of ribonucleotide reductase subunit M2 (RRM2) gene and its prognostic significance in hepatocellular carcinoma (HCC). Methods The HCC transcriptome data and clinical data from The Cancer Genome Atlas (TCGA) database, the expression data of RRM2 in HCC and adjacent tissues was extracted, and COX single factor and multivariate were used to analyze the clinical and prognostic correlation between RRM2 and HCC patients. The Human Protein Atlas (HAP) database was used to analyze the expression of RRM2 protein in HCC. Results RRM2 protein and mRNA were highly expressed in adjacent tissues, and the expression level of RRM2 in stage Ⅰ and stage Ⅱ HCC tissue was significantly higher than that in stage Ⅲ and stage Ⅳ cancer tissue (P<0.01). Statistical analysis showed that the expression of RRM2 was negatively correlated with the prognosis of HCC patients (P<0.01). COX univariate and multivariate analysis showed that the expression level of RRM2 and TNM stage in HCC tissues were independent factors affecting the prognosis of HCC. Conclusion RRM2 may play a promoting role in the occurrence and development of HCC and is an independent risk factor affecting the prognosis of HCC patients. It may become a molecular marker for early diagnosis of HCC and a potential indicator for prognosis, providing a theoretical basis for the development of RRM2 inhibitors.

R979.1